For example, in PAH where BMP signaling is compromised in endothelial cells, TGFβ signaling is enhanced and inhibition of TGFβ signaling has been shown to offer therapeutic benefit in preclinical PAH models (48, 49). This evidence concerns the gene TGFB1 and pulmonary arterial hypertension.